Efficacy and Safety of Natamycin and Lactulose Vaginal Suppositories in Treatment of Vulvovaginal Candidiasis - Trial NCT06411314
Access comprehensive clinical trial information for NCT06411314 through Pure Global AI's free database. This Phase 3 trial is sponsored by Avva Rus, JSC and is currently Completed. The study focuses on Vulvovaginal Candidiasis, Genital. Target enrollment is 218 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Natamycin + Lactulose 100 mg + 300 mg vaginal suppositories
Interventional
combination product
Sponsor & Location
Avva Rus, JSC
Timeline & Enrollment
Phase 3
Dec 29, 2022
Sep 22, 2023
Primary Outcome
Proportion (%) of patients who achieved a clinical response (recovery) at Visit 2
Summary
The purpose is to study superior efficacy of combination of Natamycin and Lactulose
 (Natamycin 100 mg + Lactulose 300 mg vaginal suppositories) compared to Pimafucin (Natamycin
 100 mg vaginal suppositories), or Lactulose 300 mg vaginal suppositories. The second
 objective of the study was to investigate the safety of the combination suppositories in the
 treatment of vulvovaginal candidiasis in non-pregnant adult females.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06411314
Non-Device Trial